Literature DB >> 21538424

Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.

Tineke Wolters1, Rodolfo Montironi, Roberta Mazzucchelli, Marina Scarpelli, Monique J Roobol, Roderick C N van den Bergh, Pim J van Leeuwen, Robert F Hoedemaeker, Geert J L H van Leenders, Fritz H Schröder, Theodorus H van der Kwast.   

Abstract

BACKGROUND: The prostate may often harbor a prostate cancer (PC) which will not cause morbidity if left untreated. Screening for PC leads to increased detection of these insignificant cancers. Objective of this study is to compare PC detected by PSA screening at subsequent screening rounds and treated by radical prostatectomy (RP) with PC incidentally found in cystoprostatectomy specimens.
METHODS: Radical prostatectomy specimens of 617 screen-detected PC were compared with 123 PC identified in cystoprostatectomy specimens. Surgical specimens were systematically examined and stage, grade, tumor volume were recorded. Next, we classified PC as clinically significant or insignificant (i.e., tumor volume <0.5 cm(3), absence of Gleason pattern 4/5, organ confined). Pathological features of incidentally detected PC were compared with PC detected in subsequent screening rounds and with screen-detected T1c PC.
RESULTS: Screen-detected PC overall were more often multifocal, larger in volume, more advanced in tumor stage and of higher grade, while the frequency of insignificant PC was lower as compared to those in cystoprostatectomy specimens. This effect became more pronounced during subsequent screening rounds. Screen-detected T1c PC were also more often multifocal (73% vs. 37%) in average fivefold larger (0.85 cm(3) vs. 0.16 cm(3)), less often organ confined (81% vs. 94%), and less frequently clinically insignificant (33% vs. 81%).
CONCLUSIONS: Screen-detected (T1c) PC treated with RP shows more aggressive features than incidentally found PC. This PSA screening-related selection seems to be mainly driven by tumor volume and-in later screening rounds-by the preferential treatment by prostatectomy of more aggressive PC.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21538424     DOI: 10.1002/pros.21415

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

Review 1.  Prognostic prostate tissue biomarkers of potential clinical use.

Authors:  Theodorus H Van der Kwast
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

2.  Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy.

Authors:  Shulin Wu; Sharron X Lin; Min Lu; Alexander O Subtelny; Zongwei Wang; Douglas M Dahl; Aria F Olumi; Chin-Lee Wu
Journal:  Int Urol Nephrol       Date:  2019-06-10       Impact factor: 2.370

Review 3.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

Review 4.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

Review 5.  Concomitant bladder cancer and prostate cancer: challenges and controversies.

Authors:  Antonio Lopez-Beltran; Liang Cheng; Francesco Montorsi; Maria Scarpelli; Maria R Raspollini; Rodolfo Montironi
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

6.  Preoperative findings, pathological stage PSA recurrence in men with prostate cancer incidentally detected at radical cystectomy: our experience in 242 cases.

Authors:  Pietro Pepe; Filippo Fraggetta; Antonio Galia; Paolo Panella; Michele Pennisi; Maurizio Colecchia; Francesco Aragona
Journal:  Int Urol Nephrol       Date:  2014-02-01       Impact factor: 2.370

Review 7.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

8.  Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens.

Authors:  Berna Aytac; Hakan Vuruskan
Journal:  World J Surg Oncol       Date:  2011-07-20       Impact factor: 2.754

Review 9.  Management of low risk prostate cancer-active surveillance and focal therapy.

Authors:  Laurence Klotz; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675

Review 10.  The current and future role of magnetic resonance imaging in prostate cancer detection and management.

Authors:  Jan Philipp Radtke; Dogu Teber; Markus Hohenfellner; Boris A Hadaschik
Journal:  Transl Androl Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.